Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report discusses a 5-year-old Persian cat with feline eosinophilic granuloma complex, which responded positively to prednisone and topical corticosteroids, eliminating itching and promoting fur regrowth without relapse.

This report describes a case of a woman with ophiasis-pattern alopecia areata who experienced significant hair regrowth and maintained it for 6 months after treatment with dupilumab, though she eventually relapsed.

In this case study, two middle-aged patients with pruritic scalp erosions were diagnosed with localized pemphigus vulgaris, which resolved without relapse after treatment with low-dose oral prednisone and intralesional triamcinolone acetonide.

In this retrospective study, 75% of patients with alopecia areata responded well to an 8-week oral methylprednisolone tapering treatment, but 28.4% relapsed within an average of 5.5 months; young age and extensive alopecia predicted poorer responses, and low vitamin D was linked to relapse.

This case report describes a non-thymoma-associated exfoliative dermatitis in an 8-year-old cat, where treatment with cyclosporine A alongside prednisolone and antibiotics resolved skin lesions without relapse after an initial recurrence.

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

This study found that while both microneedling-assisted methotrexate and triamcinolone acetonide treatments led to improvements in recalcitrant alopecia areata, methotrexate-treated areas had significantly better outcomes in terms of SALT score reduction, patient satisfaction, and relapse rates, suggesting its superior short-term efficacy.

This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.

In this case report, a 7-year-old girl with alopecia areata showed approximately 80% hair regrowth and resolved scalp symptoms after four months of individualized homeopathic treatment, maintaining clinical improvement with minimal relapse over more than a year.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This review outlines the major health consequences of anabolic-androgenic steroid abuse, with a focus on sexual and reproductive issues, and suggests management prioritizes cessation and relapse prevention due to lack of robust randomized trials.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This case report described a Persian cat with psychogenic alopecia and secondary dermatitis linked to environmental stress, which improved with antihistamine therapy, diet changes, and owner interaction, but relapsed in a high cat population setting.

This case report describes a 33-year-old male with treatment-resistant psoriasis who experienced complete resolution of symptoms and hair regrowth after following an integrated Shodhana-Shamana chikitsa regimen, with no relapse noted at follow-up, suggesting its potential for sustainable Ekakustha management.

This case report observed that an integrated Shodhana-Shamana treatment protocol effectively managed treatment-resistant Ekakustha (plaque psoriasis), resulting in complete symptom resolution and no relapse at follow-up.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This review highlights the potential role of vitamin D and its analogs in managing alopecia areata, noting that vitamin D deficiency and altered receptor expression may be linked to disease severity and that supplementation could help reduce severity and relapse rates.

In this study, intravenous corticosteroid pulse therapy for rapidly progressive alopecia areata showed that 74.5% of patients achieved a good response in the long-term, and a revised scoring system predicted relapse risk effectively in cases with preceding infectious symptoms.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This case report highlights an atypical presentation of favus in an immunocompetent adult, where a psoriasiform plaque over the 'bindi' area was successfully treated with systemic itraconazole, achieving complete resolution without relapse. Simple stains proved essential for diagnosis in this resource-limited setting.

In this case, ayurvedic medicines were reported to effectively manage a patient with alopecia areata, with fewer side effects and reduced relapse rates compared to conventional treatments.

In this study, a 40-year-old man with hair loss showed complete hair regrowth and no relapse 24 weeks after receiving umbilical cord mesenchymal stem cell and secretome injections, highlighting their potential for alopecia treatment, although further research involving larger populations is needed.

This case study reports that a 14-year-old female with loose anagen hair syndrome and trichotillomania initially improved with topical minoxidil and counseling, but relapsed after a year, highlighting treatment challenges.

The authors concluded that increasing regulatory T cells in patients with alopecia areata may improve hair follicle regeneration by reducing autoimmune responses, suggesting a potential new therapeutic approach since current treatments are often ineffective with high relapse rates.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

This review found that while about 60% of patients with alopecia areata responded to liquid nitrogen cryotherapy in existing studies, no significant efficacy difference was observed compared to intralesional steroid injections, though relapse rates may be lower with cryotherapy.

In this study, intralesional triamcinolone acetonide was found to be more effective than platelet rich plasma and placebo for moderate to severe alopecia areata, but had a higher relapse rate.